Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Requires Pharmacies To Mind Their B’s And D’s

Executive Summary

Pharmacists will have to keep careful track of prescriptions for some medicines that can be covered by Medicare Part B once the new Part D outpatient drug benefit begins in 2006

You may also be interested in...



Drug Manufacturers Face Public Opinion Challenge In Medicare Rx

Pharmaceutical manufacturers face a significant challenge in countering bad publicity about the Medicare prescription drug program, National Pharmaceutical Council President Karen Williams said at a World Congress Leadership Summit on Medicare May 23 in Washington, D.C

Drug Manufacturers Face Public Opinion Challenge In Medicare Rx

Pharmaceutical manufacturers face a significant challenge in countering bad publicity about the Medicare prescription drug program, National Pharmaceutical Council President Karen Williams said at a World Congress Leadership Summit on Medicare May 23 in Washington, D.C

CMS Reimbursement Tied To Data Collection Could Speed Coverage Decisions

Medicare reimbursement that is linked to requirements for post-marketing data collection could allow for faster coverage decisions on new medical products, American Enterprise Institute Resident Fellow Scott Gottlieb said at a Biotechnology Industry Organization/Windhover conference in Washington, D.C. April 27

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel